Serina Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax
Serina Therapeutics, Inc. (SER) reported Other Comprehensive Income (Loss), Net of Tax of -$3.28 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-12.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2023-05-12
- Serina Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2023-03-31 was -$3.28M.
- Serina Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2022-12-31 was -$2.70M.
- Serina Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2022-09-30 was -$2.44M.
- Serina Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2022-06-30 was -$2.62M.
- Serina Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$10.46M.
- Serina Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2021 was -$8.82M.
- Serina Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2020 was -$10.79M.
- Serina Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2019 was -$12.08M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2023-03-31 | -$3.28M 10-Q · filed 2023-05-12 | -$5.98M derived: sum of 2 quarters · filed 2023-05-12 | -$8.41M derived: sum of 3 quarters · filed 2023-05-12 | -$11.03M derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-12-31 | -$2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$5.14M derived: sum of 2 quarters · filed 2023-03-31 | -$7.76M derived: sum of 3 quarters · filed 2023-03-31 | -$10.46M 10-K · filed 2023-03-31 |
| 2022-09-30 | -$2.44M 10-Q · filed 2022-11-10 | -$5.05M derived: sum of 2 quarters · filed 2022-11-10 | -$7.76M 10-Q · filed 2022-11-10 | -$9.92M derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-06-30 | -$2.62M 10-Q · filed 2022-08-12 | -$5.32M 10-Q · filed 2022-08-12 | -$7.48M derived: sum of 3 quarters · filed 2023-05-12 | -$9.44M derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-03-31 | -$2.71M 10-Q · filed 2023-05-12 | -$4.86M derived: sum of 2 quarters · filed 2023-05-12 | -$6.82M derived: sum of 3 quarters · filed 2023-05-12 | -$9.29M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$4.11M derived: sum of 2 quarters · filed 2023-03-31 | -$6.59M derived: sum of 3 quarters · filed 2023-03-31 | -$8.82M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$1.96M 10-Q · filed 2022-11-10 | -$4.43M derived: sum of 2 quarters · filed 2022-11-10 | -$6.66M 10-Q · filed 2022-11-10 | -$9.05M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$2.47M 10-Q · filed 2022-08-12 | -$4.71M 10-Q · filed 2022-08-12 | -$7.10M derived: sum of 3 quarters · filed 2022-08-12 | -$9.63M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$2.23M 10-Q · filed 2022-05-13 | -$4.63M derived: sum of 2 quarters · filed 2022-05-13 | -$7.16M derived: sum of 3 quarters · filed 2022-05-13 | -$9.81M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$4.93M derived: sum of 2 quarters · filed 2022-03-29 | -$7.58M derived: sum of 3 quarters · filed 2022-03-29 | -$10.79M 10-K · filed 2022-03-29 |
| 2020-09-30 | -$2.53M 10-Q · filed 2021-11-12 | -$5.18M derived: sum of 2 quarters · filed 2021-11-12 | -$8.40M 10-Q · filed 2021-11-12 | -$11.11M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$2.65M 10-Q · filed 2021-08-13 | -$5.86M 10-Q · filed 2021-08-13 | -$8.58M derived: sum of 3 quarters · filed 2021-08-13 | -$11.77M derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | -$3.21M 10-Q · filed 2021-05-17 | -$5.93M derived: sum of 2 quarters · filed 2021-05-17 | -$9.12M derived: sum of 3 quarters · filed 2021-05-17 | -$12.19M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | -$2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$5.91M derived: sum of 2 quarters · filed 2021-03-31 | -$8.98M derived: sum of 3 quarters · filed 2021-03-31 | -$12.08M 10-K · filed 2021-03-31 |
| 2019-09-30 | -$3.19M 10-Q · filed 2020-11-16 | -$6.26M derived: sum of 2 quarters · filed 2020-11-16 | -$9.37M 10-Q · filed 2020-11-16 | -$12.58M derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | -$3.07M 10-Q · filed 2020-08-14 | -$6.18M 10-Q · filed 2020-08-14 | -$9.39M derived: sum of 3 quarters · filed 2020-08-14 | -$11.54M derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | -$3.11M 10-Q · filed 2020-05-14 | -$6.32M derived: sum of 2 quarters · filed 2020-05-14 | -$8.47M derived: sum of 3 quarters · filed 2020-05-14 | -$10.44M derived: sum of 4 quarters · filed 2020-05-14 |
| 2018-12-31 | -$3.21M derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-03-31 | -$5.36M derived: sum of 2 quarters · filed 2020-03-31 | -$7.34M derived: sum of 3 quarters · filed 2020-03-31 | -$7.57M 10-K/A · filed 2020-03-31 |
| 2018-09-30 | -$2.15M 10-Q · filed 2019-11-14 | -$4.12M derived: sum of 2 quarters · filed 2019-11-14 | -$4.36M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$1.98M 10-Q · filed 2019-08-14 | -$2.21M 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | -$236.00K 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | -$6.57M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |